ExpreS2ion announces exercise of 2019 warrant program

Hørsholm, Denmark, July 11, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that 167,394 warrants held by employees under the 2019 Warrant Program (“TO2”) have been fully exercised, providing ExpreS2ion SEK 805,165. The exercise has increased the number of shares by 167,394 from 36,994,712 to 37,162,106.

At an Extra General Meeting in ExpreS²ion held on May 23, 2019, it was resolved to issue warrants as part of an incentive program for employees (“the 2019 Warrant Program”, or “TO2"). The program comprised a total of 680,100 warrants, where one (1) warrant entitled to subscription of one (1) share in the Company. 612,084 were subscribed for and allocated to the employees. The warrants stipulated a subscription price of SEK 4.81 per share. The TO2 exercise period is in three months from June 1 through August 31 and is carried out in three tranches during the respective months. The 167,394 warrants cover the first of the three tranches.

Number of shares, share capital and dilution

The new shares in the first tranche have now been registered by the Swedish Companies Registration Office (Sw. Bolagsverket). The number of shares in ExpreS²ion has increased by 167,394, from 36,994,712 to 37,162,106 shares. The total share capital amounts to SEK 4,129,122.90. The dilution effect for the company's existing shareholders amounted to approximately 0.45 percent.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
 

For further information about ExpreS²ion, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
 

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion has developed a unique technology platform, ExpreS², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS²ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS²ion owns 34%. For additional information, please visit www.expres2ionbio.com.